二氟泼尼酯联合全身治疗前巩膜炎的有效性
回顾性图表 review 分析2018年1月1日至2020年1月1日接受二氟泼尼酯滴眼液联合全身治疗的前巩膜炎患者32例44眼,结果显示79.6%的眼达到临床消退,中位不活动时间9周,初始每日2-4滴者应答率89%(p=0.005),随访中11眼出现眼压升高、6眼最佳矫正视力下降≥2行、5眼白内障进展。
要点
- 二氟泼尼酯联合全身治疗使79.6%的前巩膜炎眼达到临床消退,中位不活动时间9周。
- 初始使用每日2-4滴二氟泼尼酯的眼应答率89%(p=0.005)。
- 随访中11眼眼压升高、6眼最佳矫正视力下降≥2行、5眼白内障进展。
核心结论
- 大多数接受二氟泼尼酯治疗的眼达到不活动,在全身治疗基础上加用二氟泼尼酯为控制炎症提供了替代选择。
研究设计与样本
- 回顾性图表 review,纳入2018年1月1日至2020年1月1日接受二氟泼尼酯滴眼液联合全身治疗的前巩膜炎患者32例44眼。
主要发现
- 二氟泼尼酯加用后79.6%的治疗眼达到临床消退,中位不活动时间9周(IQR 5,20)。
- 初始使用每日2-4滴的眼应答率89%(p=0.005)。
- 中位随访34周(IQR 21,74)期间,11眼出现眼压升高,6眼最佳矫正视力下降≥2行,5眼白内障进展。
- 加用二氟泼尼酯时全身治疗类型为:65%免疫抑制剂、43%泼尼松、25%非甾体抗炎药。
- 患者中位年龄57岁(IQR 52,72),59%为女性,72%为白人,59%存在相关全身疾病。
关键数值与推荐
- 主要结局为巩膜炎临床消退;次要结局包括最佳矫正视力下降≥2行、晶状体状态改变或白内障手术、眼压≥24 mm Hg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To describe the effectiveness and side-effect profile of adding difluprednate therapy to patients with anterior scleritis being treated systemically. METHODS: Retrospective chart review. Charts from all patients with anterior scleritis who were treated with topical difluprednate in addition to systemic therapy from 1 January 2018 to 1 January 2020 were reviewed. Data collected included: demographics, scleritis type, systemic diagnosis, presence of nodules or necrosis, changes in scleritis activity, intraocular pressure (IOP), number of difluprednate drops used, type of systemic treatment used, best-corrected visual acuity (BCVA) and lens status. The primary outcome was clinical resolution of scleritis. Secondary outcomes included BCVA loss ≥2 lines, change in lens status or cataract surgery and IOP ≥24 mm Hg. RESULTS: Thirty-two patients (44 eyes) were analysed. The median age was 57 years (IQR 52, 72); 59% were female; 72% were Caucasian. An associated systemic disease was present in 59%. Systemic therapies used when difluprednate was added were: 65% immunosuppressive agents, 43% prednisone and 25% non-steroidal anti-inflammatory drugs. The addition of difluprednate resulted in clinical resolution in 79.6% of the treated eyes. Median time to inactivity was 9 weeks (IQR 5, 20). Eyes initially using 2-4 drops per day had a higher response rate (89%, p=0.005). Over a median follow-up of 34 weeks (IQR 21, 74), 11 eyes had IOP elevation; 6 eyes lost ≥2 lines of BCVA, 5 eyes had cataract progression. CONCLUSION: Most eyes treated with difluprednate achieved inactivity. The addition of difluprednate to systemic therapies provides an alternative to achieve control of inflammation.
引用
- Liberman P, Thorne J, Burkholder B, et al. Effectiveness of difluprednate in addition to systemic therapy for the treatment of anterior scleritis. Br J Ophthalmol. 2024. PMID: 37666642. doi:10.1136/bjo-2022-322841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。